증권
Clinical Trials Provider Soars, Clears Buy Point On Solid Q2 Results- H2 2026 Distressed Outlook: Elevated cost of capital, software debt in focus
- IRS will automatically wipe late-filing penalties up to 25% for taxpayers with a 3-year clean record
- Unilever Finally Finds Its Volume Button
- Navigating Vistance Networks’ (VISN) Asset Sales and Dividends
- Atlassian’s (TEAM) Strategic Position in the AI Landscape
- Night View Capital Trimmed Oracle (ORCL) After Robust Cloud Gains
- Autodesk (ADSK) Holds Stable Position in the Market
- ServiceNow (NOW) Looks Appealing Amid Workflow Automation and AI Adoption
- Salesforce’s (CRM) Impact on AI Deployment in Corporate Environments
- Fed meeting live: Federal Reserve expected to hold rates steady, but Iran war adds tension
- 6 members of Congress have bought SpaceX stock, including one Democrat
- Bitcoin and ethereum prices today, Tuesday, July 28, 2026: Crypto prices slide ahead of Fed meeting
- Boeing Shares Fight To Regain Support; Q2 Results Don't Help
- Coca-Cola raises earnings guidance as CFO says Diet Coke is having 'a moment'
- Boeing posts wider loss than expected as Air Force One costs weigh on resultsBoeing took a $280 million charge on its long-delayed Air Force One program.
- Pentair Shares Drop After Revenue Miss Overshadows Earnings Beat
- What Makes Celsius Holdings (CELH) an Attractive Bet?
- World stocks hit one-month low as chip rout worsens
- Corning Shares Slide Despite Second-Quarter Earnings Beat as Guidance Disappoints